Industry
Biotechnology
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 8:44 pm
Portfolio Pulse from Avi Kapoor
June 18, 2024 | 5:39 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 5:27 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 1:28 pm
Portfolio Pulse from Avi Kapoor
June 10, 2024 | 3:25 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 2:24 pm
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 12:18 pm
Portfolio Pulse from Avi Kapoor
June 07, 2024 | 7:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.